

Tiziana Life Sciences PLC

02:34 24 Aug 2020

Tiziana Life Sciences hails key US patent approval that provides added protection for COVID-19 drug

Tiziana Life Sciences PLC (LON:TILS, NASDAQ:TLSA) has received a US patent for its TZLS-501 antibody technology being developed to treat the life-threatening effects of the coronavirus (COVID-19).

Protection has been granted around the "methods and use" of anti-IL 6 and IL-6 receptor monoclonal antibodies for both protective (prophylactic) and therapeutic use.

WATCH: Tiziana Life Sciences receives US patent for Covid-19 treatment

The grant of this additional patent on TZLS-501 is of "particular significance" for the potential treatment of COVID-19 and other pulmonary diseases such as acute respiratory distress syndrome, the company said.

In the case of COVID, the treatment offers the promise of providing immediate respite if the drug is inhaled directly using a handheld nebuliser.

"The granting of this patent along with our previously filed patent application on inhalation delivery of anti-IL-6 mAbs strengthens our intellectual property for the treatment of lung diseases," Tiziana chief executive, Dr Kunwar Shailubhai said in a statement.

He added that the company is "expediting" the clinical development of TZLS-501. So, work is ongoing to scale-up manufacturing, develop the inhalation delivery system and to safety test it.

Completion of these studies will enable Tiziana to file an investigational new drug application and initiate a clinical trial in COVID-19 patients by the first quarter of next year, said Shailubhai.

"Subsequently, we plan to use TZLS-501 with the same inhalation delivery technology for the treatment of patients with acute respiratory distress syndrome," he added.

Price: 187.31

Market Cap: £354.25 m

1 Year Share Price Graph



October 2019 May 2020 October 2020

Share Information

Code: TILS

Listing: AIM

52 week	High	Low
	300	23.5

Sector: Pharma & Biotech

Website: www.tizianalifesciences.com

Company Synopsis:

Tiziana Life Sciences is a dual-listed (NASDAQ:TLSA, AIM:TILS) clinical stage biotechnology company that specializes in the developing transformative therapies for inflammatory diseases and cancer related to the liver. Our clinical pipeline includes drug assets for NASH, Crohn's, and hepatocellular carcinoma.

action@proactiveinvestors.com

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 action@proactiveinvestors.com

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Tiziana Life Sciences PLC named herein, including the promotion by the Company of Tiziana Life Sciences PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).